We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Arecor Therapeutics

Formulation expertise exemplified in diabetes

Update | 20 January 2022

ANGLE

FDA approval awaited, LDT data expected H122

Update | 17 January 2022

Allergy Therapeutics

Commercialising and developing a differentiated portfolio

Update | 13 January 2022

Nexstim

Admirable execution on 2021 strategic goals

Update | 12 January 2022

Avacta

AffiDX LFT sales paused to improve Omicron detection

Lighthouse | 10 January 2022

Avacta

Consumer testing CE mark received for AffiDX LFT

Lighthouse | 22 December 2021

Futura Medical

Management update details degree of 2021 progress

Lighthouse | 20 December 2021

Avacta

AVA6000 set to start US Phase I studies in early-2022

Lighthouse | 29 November 2021

MaxCyte

Nkarta signs SPL to accelerate its NK cell therapies

Lighthouse | 04 November 2021

Allergy Therapeutics

Positive top line G309 results for Grass MATA MPL

Lighthouse | 25 October 2021
397 results found.